Back to top
more

Adicet Bio (ACET)

(Real Time Quote from BATS)

$1.95 USD

1.95
659,955

-0.15 (-7.14%)

Updated Apr 24, 2024 11:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Adicet Bio (ACET) Stock Might be a Great Pick

by Zacks Equity Research

Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

by Zacks Equity Research

Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

by Zacks Equity Research

Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

by Zacks Equity Research

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

by Zacks Equity Research

Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

by Zacks Equity Research

Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.

Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up

by Zacks Equity Research

Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA

by Zacks Equity Research

Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

by Zacks Equity Research

Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use

by Zacks Equity Research

Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.

AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

by Zacks Equity Research

AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

by Zacks Equity Research

Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why

by Zacks Equity Research

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

by Zacks Equity Research

Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

by Zacks Equity Research

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

by Zacks Equity Research

Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

by Zacks Equity Research

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

by Zacks Equity Research

Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

by Zacks Equity Research

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer

by Zacks Equity Research

The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

by Zacks Equity Research

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.